Skip to content
Storytelling Co – Lifestyle
Author:
Candel Therapeutics
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 1, 2026
Candel Therapeutics Announces Initiation of Global Pivotal Phase 3 AURORA Trial Evaluating Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors
June 30, 2026
Candel Therapeutics Appoints Mark Sims as Chief Commercial Officer
June 25, 2026
Candel Therapeutics Announces Publication in The Lancet Oncology of Pivotal Phase 3 Data Demonstrating Significant Improvement in Disease-Free Survival with Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer
June 2, 2026
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 1, 2026
←
Previous Page
1
2
3